# A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

> **NCT04272203** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Non Small Cell Lung Cancer
- Cancer

## Interventions

- **DRUG:** ABBV-184

## Key facts

- **NCT ID:** NCT04272203
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-05
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-06-27
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272203, "A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04272203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*